# NATIONAL JEWISH HEALTH: 1/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | NATIONAL JEWISH HEALTH |
| Location | DENVER, CO |
| Project | 1/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease |
| Project number | 1UG3HL183035-01A1 |
| Mechanism | UG3 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,000,770 |
| Awarded | 2026-09-08 |
| Project period | 2026-09-04 to 2031-05-31 |
| UEI | VLQKFEEJ3NE9 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11451497). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.